Sagimet Biosciences Inc.: Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates
Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025 Denifanstat received Breakthrough Therapy designation from FDA for MASH Clearance of Investigation ...
Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates
Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025Denifanstat received Breakthrough Therapy ...
Likewise on MSN6dOpinion
7 Lawless Western Movies to Channel Your Inner Gunslinger
Explore the wild frontiers of cinema with these seven remarkable Western movies that span genres and tell riveting tales of ...